

**Remarks/Arguments**

Applicants have amended the specification to provide the priority claim. The claims have been amended to remove multiple dependencies and to otherwise place the claims in an appropriate U.S. format.

The following claims have been added:

- Clam 17 - basis for this claim is page 15, lines 2-3 of the published PCT application.
- Clam 18 - basis for this claim is page 15, line 12 of the published PCT application.
- Clam 19 - basis for this claim is page 34, lines 5-26 of the published PCT application.
- Clam 20 - a claim directed towards the compounds of the Examples.
- Claims 21-23 - basis for these claims is to be found at page 53 line 24 - page 54 line 4 of the published PCT application.


No new matter has been added by these amendments.

The above amendments have been made without prejudice to Applicants right to prosecute any cancelled subject matter in a timely filed continuation application.

Applicants believe the application is in condition for allowance, which action is respectfully requested.

Although Applicants believe no fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 50-3231, referencing Attorney Docket No. 101159-1P US.

Respectfully submitted,



---

Name: Lucy Padget  
Dated: January 26, 2006  
Reg. No.: L0074  
Phone No.: 781-839-4182  
Global Intellectual Property, Patents  
AstraZeneca R&D Boston  
35, Gatehouse Drive  
Waltham, MA 02451